Tag: Osteonecrosis of the jaw

According to prescribing information, approximately one in five patients taking oral bisphosphonates like alendronate experience gastrointestinal adverse effects related to the esophagus. Therefore, understanding which patient should not be prescribed alendronate is crucial to prevent serious complications and ensure patient safety. This guide provides a detailed overview of the conditions and circumstances that contraindicate the use of this common osteoporosis medication.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious side effect, with the risk significantly higher for patients on specific high-dose, intravenous medications compared to those on oral alternatives. Understanding which med is most likely to cause osteonecrosis of the jaw involves looking at antiresorptive drugs like bisphosphonates and denosumab, particularly in an oncology setting.

According to the National Institutes of Health, bisphosphonates are among the most widely used drugs globally, with millions of prescriptions annually. But **what are bisphosphonates** and how do they work to protect bone health? These medications are potent inhibitors of bone resorption, used to treat conditions like osteoporosis and Paget's disease.

The risk of developing osteonecrosis of the jaw (ONJ) from Reclast is extremely rare in osteoporosis patients, with an estimated incidence of less than 0.15%. However, it is a serious potential side effect, and jaw pain can be an early indicator of this condition.

According to the American Association of Oral and Maxillofacial Surgeons (AAOMS), the risk of medication-related osteonecrosis of the jaw (MRONJ) is significantly higher for patients on high-dose intravenous bisphosphonates or denosumab, with incidence ranging from 1% to 10%. This article will explore which of the following medications increases the risk of medication-related osteonecrosis of the jaw, outlining the associated risk factors and management strategies.

Over 1.5 million prescriptions for oral bisphosphonates like alendronate are written each year, yet the medication is not safe for everyone. It is critical to understand **who should not take alendronate** to prevent serious adverse effects.

According to clinical data for Zoledronic acid (the active ingredient in Zolasta), fever was reported in up to 44% of patients receiving the medication for cancer-related hypercalcemia. For anyone prescribed this treatment, understanding **what are the side effects of the drug Zolasta** is critical, as reactions can vary significantly in severity and duration.

Millions of people worldwide take alendronate, a bisphosphonate medication, to manage bone density conditions like osteoporosis. While dental surgery requires special precautions for those on this medication due to risks like osteonecrosis of the jaw (ONJ), routine dental cleanings are generally considered safe while taking alendronate.

Contrary to common belief, the osteoporosis drug Fosamax was never the subject of a complete FDA recall in the United States [1.3.1]. The question 'Why was Fosamax taken off the market?' stems from its brand-name decline after its patent expiration in 2008 and major safety controversies [1.7.4].

While alendronate is highly effective for treating osteoporosis, its use has been shadowed by controversy, largely due to reports of rare but serious side effects, most notably atypical femur fractures and osteonecrosis of the jaw. The controversy with alendronate is further fueled by prolonged litigation against its manufacturer, Merck, for alleged failure to provide adequate warnings.